Vertex Pharmaceuticals Inc has gained US approval for the first new type of painkiller in more than two decades, paving the way for a safer alternative to addictive opioids that have been linked to hundreds of thousands of deaths.
Vertex’s pill, called Journavx, received US Food and Drug Administration clearance to treat moderate to severe acute pain, a statement said on Thursday. The wholesale acquisition cost for the twice-daily medicine is set at US$15.50 per 50 milligram tablet, Vertex said.
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, surgeries, and other injuries and procedures. More than half a million US deaths were linked to overdoses of the addictive drugs from 1999 to 2019, official figures show, with more than 70,000 in the year through June last year alone.
Photo:AP
While some fatalities involved use of illicit drugs, many people begin taking them after they lost access to prescribed opioids, leading doctors and health officials to look for other options.
Vertex’s drug has been hailed as a scientific breakthrough, because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can lead patients to ramp up doses to dangerous levels. It is a key to Vertex’s strategy of diversifying beyond its core business centered on cystic fibrosis treatments.
While some analysts predict the painkiller would become a multibillion-dollar product for a company needing a growth driver, questions remain about its price and commercial potential. Health insurers and hospitals might continue steering patients to opioids, which — while dangerous — are cheap and effective.
Vertex has been pressing Congress to create policies that would help its product succeed. For example, the No Pain Act, which provides extra Medicare reimbursement to hospitals that prescribe alternatives to opioids, went into effect this year.
The company plans to focus on selling its drug to the about 2,000 US hospitals that see about two-thirds of patients in acute pain, chief operating officer Stuart Arbuckle said.
Boston-based Vertex, the maker of cystic fibrosis treatments like the blockbuster Trikafta, has worked for more than two decades to develop a nonaddictive pain drug. Journavx, also called suzetrigine, blocks a structure in the nerve cells that send pain signals to the brain.
In late-stage studies of patients with acute pain after surgery, Vertex’s drug worked better than a placebo, but failed to reduce pain faster than a combination of acetaminophen, better known as Tylenol, and an opioid. That could present a challenge for Vertex, as new drugs typically must outperform what is already on the market to gain traction.
Vertex is studying the same pill to treat chronic pain lasting at least three months, which affects about 50 million Americans. The company encountered a setback in December when a mid-stage trial showed the drug failed to work better than a placebo in lower back pain, causing the shares to plunge.
A ship that appears to be taking on the identity of a scrapped gas carrier exited the Strait of Hormuz on Friday, showing how strategies to get through the waterway are evolving as the Middle East war progresses. The vessel identifying as liquefied natural gas (LNG) carrier Jamal left the Strait on Friday morning, ship-tracking data show. However, the same tanker was also recorded as having beached at an Indian demolition yard in October last year, where it is being broken up, according to market participants and port agent’s reports. The ship claiming to be Jamal is likely a zombie vessel that
Cannabis-based medicines have shown little evidence of effectiveness for treating most mental health and substance-use disorders, according to a large review of past studies published in a major medical journal on Monday. Medical use of cannabinoids has been expanding, including in the US, Canada and Australia, where many patients report using cannabis products to manage conditions such as anxiety, post-traumatic stress disorder and sleep problems. Researchers reviewed data from 54 randomized clinical trials conducted between 1980 and May last year involving 2,477 participants for their analysis published in The Lancet. The studies assessed cannabinoids as a primary treatment for mental disorders or substance-use
NATIONWIDE BLACKOUT: US President Donald Trump cut off Venezuelan oil shipments to Cuba, strangling the Caribbean island’s already antiquated grid Cuba’s national electric grid collapsed on Monday, the nation’s grid operator said, leaving about 10 million people without power amid a US-imposed oil blockade that has crippled the already obsolete generation system. Grid operator UNE on social media said that it is investigating the causes of the blackout, the latest in a series of widespread outages that last for hours or days and that this weekend sparked a rare violent protest in the communist-run nation. Officials ruled out a major power plant failure, but had still not pinpointed the root cause of the grid collapse, suggesting a problem with transmission. Officials said that
CONSERVING FUEL: State institutions are to operate only four days a week starting tomorrow, with the measures also applying to schools and universities Sri Lanka on Monday announced a shorter working week to conserve its scarce fuel reserves as it prepares for a prolonged war in the Middle East. The Strait of Hormuz, a key waterway through which about 20 percent of global exports pass in peacetime, has been effectively closed by Iran in retaliation over the US and Israeli war against it, now in its third week. Sri Lankan Commissioner-General of Essential Services Prabath Chandrakeerthi said state institutions would operate only four days a week starting tomorrow. The new austerity measures would also apply to schools and universities, and would remain in place indefinitely. “We are
RSS